| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’
|
Schöffski, P.
|
|
|
29 |
3 |
p. 758-765
|
artikel
|
| 2 |
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial
|
Witzig, T.E.
|
|
|
29 |
3 |
p. 707-714
|
artikel
|
| 3 |
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
|
Tabernero, J.
|
|
|
29 |
3 |
p. 602-609
|
artikel
|
| 4 |
A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with an MYC-regulated SNP rs6983267
|
Gong, J.
|
|
|
29 |
3 |
p. 632-639
|
artikel
|
| 5 |
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial
|
Gennari, A.
|
|
|
29 |
3 |
p. 661-668
|
artikel
|
| 6 |
A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)
|
Frikha, M.
|
|
|
29 |
3 |
p. 731-736
|
artikel
|
| 7 |
Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer
|
Khosrow-Khavar, F.
|
|
|
29 |
3 |
p. 744-748
|
artikel
|
| 8 |
Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
|
Herrera, A.F.
|
|
|
29 |
3 |
p. 724-730
|
artikel
|
| 9 |
Body mass index and 20 specific cancers: re-analyses of dose–response meta-analyses of observational studies
|
Choi, E.K.
|
|
|
29 |
3 |
p. 749-757
|
artikel
|
| 10 |
Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer
|
Schou, J.V.
|
|
|
29 |
3 |
p. 610-615
|
artikel
|
| 11 |
Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?
|
Vivancos, A.
|
|
|
29 |
3 |
p. 532-534
|
artikel
|
| 12 |
Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer
|
Abbosh, C.
|
|
|
29 |
3 |
p. 535-537
|
artikel
|
| 13 |
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
|
Turner, N.C.
|
|
|
29 |
3 |
p. 669-680
|
artikel
|
| 14 |
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
|
Goss, G.
|
|
|
29 |
3 |
p. 687-693
|
artikel
|
| 15 |
Concurrent cisplatin and radiotherapy versus cetuximab and radiotherapy, an unsolved problem
|
Guler, O.C.
|
|
|
29 |
3 |
p. 779
|
artikel
|
| 16 |
Crossover is not associated with faster trial accrual
|
Chen, E.Y.
|
|
|
29 |
3 |
p. 776-777
|
artikel
|
| 17 |
Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer
|
Otsubo, K.
|
|
|
29 |
3 |
p. 780-781
|
artikel
|
| 18 |
Editorial Board
|
|
|
|
29 |
3 |
p. i-ii
|
artikel
|
| 19 |
ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma
|
Buske, C.
|
|
|
29 |
3 |
p. 544-562
|
artikel
|
| 20 |
First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma
|
Turajlic, S.
|
|
|
29 |
3 |
p. 542-543
|
artikel
|
| 21 |
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)
|
Sharma, P.
|
|
|
29 |
3 |
p. 654-660
|
artikel
|
| 22 |
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma
|
Krug, A.K.
|
|
|
29 |
3 |
p. 700-706
|
artikel
|
| 23 |
Interim monitoring for non-inferiority trials: minimizing patient exposure to inferior therapies
|
Korn, E.L.
|
|
|
29 |
3 |
p. 573-577
|
artikel
|
| 24 |
Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE
|
Gaspar, N.
|
|
|
29 |
3 |
p. 766-771
|
artikel
|
| 25 |
Medical oncologists’ perception of antiestrogen therapy benefit in premenopausal women with hormone receptor-positive early-stage breast cancer
|
Patel, R.
|
|
|
29 |
3 |
p. 772-773
|
artikel
|
| 26 |
Next-generation immunotherapies for lymphoma: one foot in the future
|
Manson, G.
|
|
|
29 |
3 |
p. 588-601
|
artikel
|
| 27 |
Nivolumab in non-small-cell lung cancer with EGFR mutation
|
Yoshida, H.
|
|
|
29 |
3 |
p. 777-778
|
artikel
|
| 28 |
Outcome in colorectal cancer—tumour, stroma and so much more
|
Park, J.H.
|
|
|
29 |
3 |
p. 534-535
|
artikel
|
| 29 |
Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution
|
Venkatesan, S.
|
|
|
29 |
3 |
p. 563-572
|
artikel
|
| 30 |
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
|
Swain, S.M.
|
|
|
29 |
3 |
p. 646-653
|
artikel
|
| 31 |
Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding
|
Yan, F.
|
|
|
29 |
3 |
p. 694-699
|
artikel
|
| 32 |
Phase I–II trial designs: how early should efficacy guide the dose recommendation process?
|
Paoletti, X.
|
|
|
29 |
3 |
p. 540-541
|
artikel
|
| 33 |
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
|
Condorelli, R.
|
|
|
29 |
3 |
p. 640-645
|
artikel
|
| 34 |
Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia
|
Khoury, H.J.
|
|
|
29 |
3 |
p. 578-587
|
artikel
|
| 35 |
Progestin-associated shift of meningioma mutational landscape
|
Peyre, M.
|
|
|
29 |
3 |
p. 681-686
|
artikel
|
| 36 |
Prognostic markers for colorectal cancer: estimating ploidy and stroma
|
Danielsen, H.E.
|
|
|
29 |
3 |
p. 616-623
|
artikel
|
| 37 |
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy
|
Friedlander, M.
|
|
|
29 |
3 |
p. 737-743
|
artikel
|
| 38 |
RAISEing VEGF-D’s importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients
|
Carmeliet, P.
|
|
|
29 |
3 |
p. 529-532
|
artikel
|
| 39 |
Re-aligning the ASCO and ESMO clinical benefit frameworks for modern cancer therapies
|
Del Paggio, J.C.
|
|
|
29 |
3 |
p. 773-774
|
artikel
|
| 40 |
Reply to the letter to the editor ‘Concurrent cisplatin and radiotherapy versus cetuximab and radiotherapy, an unsolved problem’ by Guler et al.
|
Ghi, M.G.
|
|
|
29 |
3 |
p. 779-780
|
artikel
|
| 41 |
Reply to the letter to the editor ‘Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies’
|
Cherny, N.I.
|
|
|
29 |
3 |
p. 774-775
|
artikel
|
| 42 |
Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers
|
Fossard, G.
|
|
|
29 |
3 |
p. 715-723
|
artikel
|
| 43 |
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
|
Yamada, Y.
|
|
|
29 |
3 |
p. 624-631
|
artikel
|
| 44 |
Table of Contents
|
|
|
|
29 |
3 |
p. iii-vi
|
artikel
|
| 45 |
The ESMO Precision Medicine Glossary
|
Jørgensen, J.T.
|
|
|
29 |
3 |
p. 781-782
|
artikel
|
| 46 |
The US Food and Drug Administration’s use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation
|
DeLoughery, E.P.
|
|
|
29 |
3 |
p. 527-529
|
artikel
|
| 47 |
Uncovering the links between systemic hormones and oncogenic signaling in the pathogenesis of meningioma
|
Du, Z.
|
|
|
29 |
3 |
p. 537-540
|
artikel
|
Tijdschrift beschrijving